Long-lasting mRNA-encoded interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers dlvr.it/T5MwQV

Data from the control arm of adjuvant bladder cancer trials (CM274 and Ambassador250) suggests ~35% get no further therapy after relapse (accounting for censoring). Excellent sites. Chemo is globally available. Regular CT follow should catch early & treat. Any easy explanations?

#APCCC24 's Session 1 is shaping up to be an insightful journey through the treatment and management of
>>high-risk and locally advanced prostate cancer<<.
Under the guidance of chairs Neha Vapiwala and Neal Shore, and featuring insights from experts like Martin E. Gleave,…

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis dlvr.it/T5J2kT

The Lancet Commission on prostate cancer projects a X2️⃣ 📈of cases by 2040, highlighting the urgent need for innovations in diagnosis & treatment.
👏Kudos to the authors for mapping a path to better men’s health worldwide.

OncoAlert Prostate Cancer Foundation Nick James Advanced Prostate Cancer Consensus Conference…

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness dlvr.it/T5LWhM

Application of next-generation imaging in biochemically recurrent prostate cancer | Prostate Cancer and Prostatic Diseases nature.com/articles/s4139…

Unleashing a safe and potent pro-senescence anti-tumor strategy dlvr.it/T5H0yF

NEW content online! Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications dlvr.it/T5Fz27

Location, location, location: Protein kinase nanoclustering for optimised signalling output. elifesciences.org/articles/93902…

💫🌟🔍 Exploring the Depths of Cancer's Spread: Insights from Circulating Tumor Cells (CTCs)🌟💫
OncoAlert AACR aacrjournals.org/cancerdiscover…
1️⃣Innovative Advances: Enhancements in CTC isolation and multiomics technologies have revolutionized our understanding of the molecular…

Out on European Urology
New analysis from IMvigor010 trial suggests circulating tumor DNA🧬positivity predicts survival benefit with adjuvant atezolizumab in muscle-invasive urothelial carcinoma post-surgery.

✅Reduction in ctDNA levels correlates with longer survival.…

Today is #WorldHealthDay 🌍 A new American Cancer Society & IARC Global Cancer Statistics report reveals that #LungCancer is the most frequently diagnosed cancer worldwide. Investing in prevention is the key to saving lives across the globe.

Full report: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

💫🌟🔬 Major updates from #EAU24 on prostate cancer (PCa) screening & diagnosis trials! 🚀🌟💫
OncoAlert Advanced Prostate Cancer Consensus Conference silke gillessen eaucongress.uroweb.org/game-changers-…
1️⃣ PRIME Study shows biparametric MRI equals multiparametric MRI in detecting significant PCa, suggesting a new…

#EAU2024 PSMA reporting news!!!

“COPRA is now SPARC! Standardized PSMA PET Analysis and Reporting Consensus: SPARC. Time to standardize the way we report PSMA PET” by Ken Herrmann

linkedin.com/posts/ken-herr…